Supriya Lifescience Limited — Updates, 09-12-2024: Press Release

Supriya Lifescience has achieved significant milestones in expanding its global presence. The company has received approval from Brazil’s health authority, ANVISA, for Esketamine Hydrochloride, making it the first Indian company to gain this regulatory nod for such a specialized pharmaceutical. This will allow Supriya to enhance its product offering in Brazil and other LATAM countries, addressing the demand for innovative and affordable healthcare solutions.

Additionally, Supriya has filed a patent for a novel, low-cost manufacturing technique for Atorvastatin, a critical treatment for cholesterol management and cardiovascular disease prevention. This advancement reflects the company’s commitment to reducing production costs while improving drug efficacy, thereby increasing accessibility for patients globally. With these developments, Supriya Lifescience positions itself as a key player in the international pharmaceutical market, particularly in the rapidly growing LATAM region.